home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Avadel Pharmaceuticals plc - Ordinary Share (NQ:AVDL)

21.64 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Avadel Pharmaceuticals plc - Ordinary Share

< Previous 1 2 3 4 5 6 Next >

This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 03, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 21, 2025

Via Benzinga

Avadel (AVDL) Q2 Revenue Jumps 64% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Avadel Pharmaceuticals (NASDAQ:AVDL) Surges 6.3% in Pre-Market as Q2 Earnings Crush Estimates on Strong LUMRYZ Performance ↗

August 07, 2025

Avadel Pharmaceuticals (AVDL) beats Q2 2025 estimates with $68.1M revenue and $0.10 EPS, driven by strong LUMRYZ™ adoption. Stock surges 6.3% pre-market.

Via Chartmill

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Earnings Outlook For Avadel Pharmaceuticals ↗

May 06, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

A Preview Of Avadel Pharmaceuticals's Earnings ↗

March 01, 2024

Via Benzinga

Insiders Buying Dorian LPG And 2 Other Stocks ↗

January 17, 2024

Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.

Via Benzinga

Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz ↗

July 01, 2025

ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options

Via Benzinga

Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages ↗

June 29, 2025

ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according...

Via Stocktwits

Topics ETFs Intellectual Property

Earnings Scheduled For March 3, 2025 ↗

March 03, 2025

Via Benzinga

Needham Maintains Buy Rating for Avadel Pharmaceuticals: Here's What You Need To Know ↗

December 20, 2023

Via Benzinga

3 Stocks With Robust Growth Outlooks Insiders Are Buying

February 19, 2025

Insiders are buying these three stocks. The underlying companies have robust growth outlooks and are on track to deliver in 2025.

Via MarketBeat

There May Still Be Time to Get in on These 3 Trending Biotechs

January 20, 2025

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

Via MarketBeat

Topics ETFs Economy

Avadel Pharmaceuticals Misses Earnings Estimates But Posts 150% Sales Increase From Narcolepsy Drug LUMRYZ ↗

January 09, 2025

Avadel Pharmaceuticals missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% YoY.

Via Benzinga

C-Suite Buy of the Week: Unusual Insider Trading Trends as 2025 Approaches ↗

December 19, 2024

Via Benzinga

Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

October 31, 2024

Via Benzinga

AVDL Stock Earnings: Avadel Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

AVDL stock results show that Avadel Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗

August 06, 2024

On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.

Via Investor's Business Daily

AVDL Stock Earnings: Avadel Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

AVDL stock results show that Avadel Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 28, 2024

Via Benzinga

American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 05, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Avadel Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results ↗

March 05, 2024

Avadel Pharmaceuticals plc (NASDAQ: AVDL) reported better-than-expected fourth-quarter revenue results and also issued a corporate update on Monday.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 04, 2024

Via Benzinga

Earnings Scheduled For March 4, 2024 ↗

March 04, 2024

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its fourth quarter.

Via Benzinga

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 08, 2024

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on...

Via Benzinga

Avadel Pharmaceuticals Sees Robust Uptake For Its Newly Approved Sleep Disorder Drug ↗

November 08, 2023

Avadel Pharmaceuticals plc (NASDAQ: AVDL) recognized $7.0 million in net product revenue for Q3.

Via Benzinga

Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday ↗

November 08, 2023

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com